Skip to content

AI-Powered Forecasts for Biotech Investors

Home
Tools
About
Join ScanScor
Log In
- Panel

ScanScor

The AI Biotech Breakout Prediction Strategy

ScanScor

The AI Biotech Breakout Prediction Strategy

Predictions
Scores
News Stream

phase-2a

AI Biomed Predictions

RNAZ – Phase 2a clearance may decide RNAZ’s next sharp move

ScanScor Admin / April 30, 2026

Search

Tools

Predictions
Scores
News Stream

Recent Comments

Recent Comments

1 week ago EQ – Equillium Set for Brea... – This original EQ prediction has been superseded after lat... by ScanScor Admin
2 weeks ago EQ – Equillium Set for Brea... – For EQ, I would separate three different things: Is the ... by ScanScor Admin
2 weeks ago JAGX – Jaguar Health Poised... – This is not a postmortem. It is more like a prognosis. M... by ScanScor Admin
4 weeks ago HOTH – Promising Therapeuti... – This was not a crazy prediction. It was a vulnerable micr... by ScanScor Admin
1 month ago MEIP – MEI Pharma Poised fo... – LITS (formerly MEIP) is not a viable biotech candidate f... by ScanScor Admin

Recent Posts

TRAW – MHRA decision could reawaken Traws’ deeply discounted antiviral story
RNAZ – Phase 2a clearance may decide RNAZ’s next sharp move
INAB – Microcap IN8bio could reprice sharply on fresh survival data
HIND – Phase 3 clarity could awaken this forgotten microcap biotech
GTBP – GTB-5550 clinical launch may spark GTBP’s next rebound

ScanScor empowers traders and investors with instant
AI-driven access to trusted intelligence.

🧠 Powered by real-time AI
🔍 Trained to find the moment before it moves

Terms and Conditions
About
Join the ScanScor Revolution

Disclaimer: ScanScor provides research and educational information only. Nothing on this site is financial advice or a recommendation to buy or sell securities. ScanScor does not provide forecasts or guarantee any outcomes. Past performance is not indicative of future results.

Copyright © 2026 ScanScor

Best viewed on desktop. Mobile optimization coming soon.

Scroll to Top